{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:01:35Z","timestamp":1790056895224,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T00:00:00Z","timestamp":1419897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00262-014-1642-8","type":"journal-article","created":{"date-parts":[[2014,12,29]],"date-time":"2014-12-29T06:09:43Z","timestamp":1419833383000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases"],"prefix":"10.1007","volume":"64","author":[{"given":"Sofie","family":"Wilgenhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Corthals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An M. T.","family":"Van Nuffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphn\u00e9","family":"Benteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Heirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Bonehill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Thielemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,30]]},"reference":[{"key":"1642_CR1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199\u20136206","journal-title":"J Clin Oncol"},{"key":"1642_CR2","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","volume":"30","author":"AM Eggermont","year":"2012","unstructured":"Eggermont AM, Suciu S, Testori A et al (2012) Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30:3810\u20133818","journal-title":"J Clin Oncol"},{"key":"1642_CR3","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1634\/theoncologist.2012-0368","volume":"17","author":"VK Sondak","year":"2012","unstructured":"Sondak VK, Kudchadkar R (2012) Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role? Oncologist 17:1223\u20131224","journal-title":"Oncologist"},{"key":"1642_CR4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","volume":"102","author":"S Mocellin","year":"2010","unstructured":"Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493\u2013501","journal-title":"J Natl Cancer Inst"},{"key":"1642_CR5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516","journal-title":"N Engl J Med"},{"key":"1642_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358\u2013365","journal-title":"Lancet"},{"key":"1642_CR7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107\u2013114","journal-title":"N Engl J Med"},{"key":"1642_CR8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"F Hodi","year":"2010","unstructured":"Hodi F, O\u2019Day S, McDermott D et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"1642_CR9","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517\u20132526","journal-title":"N Engl J Med"},{"key":"1642_CR10","volume-title":"Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial","author":"AM Eggermont","year":"2014","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ et al (2014) Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Meeting Abstracts, Alexandria 32"},{"key":"1642_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","volume":"24","author":"T Boon","year":"2006","unstructured":"Boon T, Coulie P, Van den Eynde B, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175\u2013208","journal-title":"Annu Rev Immunol"},{"key":"1642_CR12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135\u2013146","journal-title":"Nat Rev Cancer"},{"key":"1642_CR13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265\u2013277","journal-title":"Nat Rev Cancer"},{"key":"1642_CR14","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1158\/0008-5472.CAN-07-5898","volume":"68","author":"T Connerotte","year":"2008","unstructured":"Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie P (2008) Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res 68:3931\u20133940","journal-title":"Cancer Res"},{"key":"1642_CR15","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.4049\/jimmunol.172.11.6649","volume":"172","author":"A Bonehill","year":"2004","unstructured":"Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172:6649\u20136657","journal-title":"J Immunol"},{"key":"1642_CR16","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.gt.3302750","volume":"13","author":"A Michiels","year":"2006","unstructured":"Michiels A, Breckpot K, Corthals J, Tuyaerts S, Bonehill A, Heirman C, Thielemans K, Aerts JL (2006) Induction of antigen-specific CD8\u00a0+\u00a0cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther 13:1027\u20131036","journal-title":"Gene Ther"},{"key":"1642_CR17","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/mt.2008.77","volume":"16","author":"A Bonehill","year":"2008","unstructured":"Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, Neyns B, Thielemans K (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16:1170\u20131180","journal-title":"Mol Ther"},{"key":"1642_CR18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.1994.12.2.402","volume":"12","author":"M Mitchell","year":"1994","unstructured":"Mitchell M, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell W, Groshen S (1994) Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 12:402\u2013411","journal-title":"J Clin Oncol"},{"key":"1642_CR19","first-page":"4347","volume":"9","author":"I Astsaturov","year":"2003","unstructured":"Astsaturov I, Petrella T, Bagriacik E et al (2003) Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 9:4347\u20134355","journal-title":"Clin Cancer Res"},{"key":"1642_CR20","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-05-3396","volume":"66","author":"T Pucchio Di","year":"2006","unstructured":"Di Pucchio T, Pilla L, Capone I et al (2006) Immunization of stage IV melanoma patients with Melan-A\/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte\/dendritic cell precursors. Cancer Res 66:4943\u20134951","journal-title":"Cancer Res"},{"key":"1642_CR21","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2006.10.1709","volume":"25","author":"M Mitchell","year":"2007","unstructured":"Mitchell M, Abrams J, Thompson J et al (2007) Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 25:2078\u20132085","journal-title":"J Clin Oncol"},{"key":"1642_CR22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1078-0432.CCR-08-1231","volume":"15","author":"JM Kirkwood","year":"2009","unstructured":"Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L (2009) Immunogenicity and antitumor effects of vaccination with peptide vaccine\u00a0\u00b1\u00a0granulocyte\u2013monocyte colony-stimulating factor and\/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 15:1443\u20131451","journal-title":"Clin Cancer Res"},{"key":"1642_CR23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","volume":"364","author":"DJ Schwartzentruber","year":"2011","unstructured":"Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119\u20132127","journal-title":"N Engl J Med"},{"key":"1642_CR24","doi-asserted-by":"crossref","first-page":"20410","DOI":"10.1073\/pnas.0810114105","volume":"105","author":"J Yuan","year":"2008","unstructured":"Yuan J, Gnjatic S, Li H et al (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410\u201320415","journal-title":"Proc Natl Acad Sci USA"},{"key":"1642_CR25","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","volume":"15","author":"A Ribas","year":"2009","unstructured":"Ribas A, Comin-Anduix B, Chmielowski B et al (2009) Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267\u20136276","journal-title":"Clin Cancer Res"},{"key":"1642_CR26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CJI.0b013e31821dcb31","volume":"34","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof S, Van Nuffel AM, Corthals J et al (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34:448\u2013456","journal-title":"J Immunother"},{"key":"1642_CR27","doi-asserted-by":"crossref","unstructured":"Neyns B, Corthals J, De Greve J, De Greef C, Coulie PG, Thielemans K (2006) A cohort pilot study on therapeutic vaccination of advanced melanoma patients with dendritic cells loaded with multiple peptides or electroporated with mRNA. ASCO Meeting Abstracts 24: 18011","DOI":"10.1200\/jco.2006.24.18_suppl.18011"},{"key":"1642_CR28","doi-asserted-by":"crossref","unstructured":"Neyns B, Corthals J, Thielemans K (2007) Interferon alfa-2b treatment following therapeutic vaccination with mRNA electroporated dendritic cells results in skin depigmentation and tumor regression in patients with advanced melanoma. ASCO Meeting Abstracts 25: 8537","DOI":"10.1200\/jco.2007.25.18_suppl.8537"},{"key":"1642_CR29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0022-1759(02)00099-6","volume":"264","author":"S Tuyaerts","year":"2002","unstructured":"Tuyaerts S, Noppe S, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K (2002) Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods 264:135\u2013151","journal-title":"J Immunol Methods"},{"key":"1642_CR30","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1158\/1078-0432.CCR-08-2982","volume":"15","author":"A Bonehill","year":"2009","unstructured":"Bonehill A, Van Nuffel A, Corthals J et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15:3366\u20133375","journal-title":"Clin Cancer Res"},{"key":"1642_CR31","first-page":"405","volume":"629","author":"A Nuffel Van","year":"2010","unstructured":"Van Nuffel A, Corthals J, Neyns B, Heirman C, Thielemans K, Bonehill A (2010) Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. Methods Mol Biol 629:405\u2013452","journal-title":"Methods Mol Biol"},{"key":"1642_CR32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jim.2011.12.010","volume":"377","author":"AM Nuffel Van","year":"2012","unstructured":"Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2012) Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 377:23\u201336","journal-title":"J Immunol Methods"},{"key":"1642_CR33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/mt.2012.11","volume":"20","author":"AM Nuffel Van","year":"2012","unstructured":"Van Nuffel AM, Benteyn D, Wilgenhof S et al (2012) Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4\u00a0+\u00a0and CD8\u00a0+\u00a0T cells in melanoma patients. Mol Ther 20:1063\u20131074","journal-title":"Mol Ther"},{"key":"1642_CR34","doi-asserted-by":"crossref","first-page":"976383","DOI":"10.1155\/2013\/976383","volume":"2013","author":"D Benteyn","year":"2013","unstructured":"Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2013) Characterization of CD8(+) T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC\u2013MEL). Biomed Res Int 2013:976383","journal-title":"Biomed Res Int"},{"key":"1642_CR35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"P Kantoff","year":"2010","unstructured":"Kantoff P, Higano C, Shore N et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422","journal-title":"N Engl J Med"},{"key":"1642_CR36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0753-3322(00)80050-5","volume":"54","author":"H Hasebe","year":"2000","unstructured":"Hasebe H, Nagayama H, Sato K, Enomoto M, Takeda Y, Takahashi TA, Hasumi K, Eriguchi M (2000) Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed Pharmacother 54:291\u2013298","journal-title":"Biomed Pharmacother"},{"key":"1642_CR37","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"1642_CR38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-011-1176-2","volume":"61","author":"AM Nuffel Van","year":"2012","unstructured":"Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2012) Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61:1033\u20131043","journal-title":"Cancer Immunol Immunother"},{"key":"1642_CR39","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","volume":"24","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S, Van Nuffel AM, Benteyn D et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24:2686\u20132693","journal-title":"Ann Oncol"},{"key":"1642_CR40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/JCO.2008.16.3121","volume":"27","author":"D Pectasides","year":"2009","unstructured":"Pectasides D, Dafni U, Bafaloukos D et al (2009) Randomized phase III study of 1\u00a0month versus 1\u00a0year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 27:939\u2013944","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-014-1642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-014-1642-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-014-1642-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T12:23:14Z","timestamp":1598617394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-014-1642-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,30]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1007\/s00262-014-1642-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,30]]}}}